DeFloria Advancing Charlotte's Web Legacy as Pioneer in Cannabinoid Health, with Phase 2 Clinical Trials for Autism Botanical Drug LOUISVILLE, Colo. and WASHINGTON, Dec. 19, 2025 /PRNewswire/ - DeFloria Inc., a botanical drug development Company recognizes the Presidential Executive Order to reclassify cannabis from Schedule I to Schedule III, as a critical accelerator for cannabinoid medical innovation and regulatory reform. DeFloria is advancing a leading cannabinoid-based investigational new drug ("IND" ...